InMed Pharmaceuticals (INM) Retained Earnings (2021 - 2025)
Historic Retained Earnings for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$121.0 million.
- InMed Pharmaceuticals' Retained Earnings fell 676.91% to -$121.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$121.0 million, marking a year-over-year decrease of 676.91%. This contributed to the annual value of -$117.2 million for FY2025, which is 748.3% down from last year.
- According to the latest figures from Q4 2025, InMed Pharmaceuticals' Retained Earnings is -$121.0 million, which was down 676.91% from -$119.0 million recorded in Q3 2025.
- Over the past 5 years, InMed Pharmaceuticals' Retained Earnings peaked at -$77.8 million during Q3 2021, and registered a low of -$121.0 million during Q4 2025.
- For the 5-year period, InMed Pharmaceuticals' Retained Earnings averaged around -$103.3 million, with its median value being -$104.7 million (2023).
- Per our database at Business Quant, InMed Pharmaceuticals' Retained Earnings plummeted by 2459.23% in 2022 and then tumbled by 601.24% in 2024.
- Quarter analysis of 5 years shows InMed Pharmaceuticals' Retained Earnings stood at -$82.1 million in 2021, then fell by 20.65% to -$99.1 million in 2022, then fell by 6.41% to -$105.4 million in 2023, then decreased by 7.51% to -$113.3 million in 2024, then fell by 6.77% to -$121.0 million in 2025.
- Its last three reported values are -$121.0 million in Q4 2025, -$119.0 million for Q3 2025, and -$117.2 million during Q2 2025.